BSE filing, NSE: EFCIL. Summary written from the filing by ALFA Finder's alert engine.
EFC (I) Ltd: key numbers
- Share price
- ₹172.43
- Market cap
- ₹2,586 Cr
- Revenue (annual)
- ₹1,037 Cr
- Net profit (annual)
- ₹231.6 Cr
- P/E (TTM)
- 10.5×Sector 33.7×
- Promoter holding
- 56.08%+0.00% QoQ
- FII holding
- 1.02%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from EFC (I) Ltd
All →EFC (I) Board Meeting Date
EFC (I) will hold a board meeting on 2 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The filing gives notice only, so the agenda is proposed.
EFC (I) Merger & Restructuring
NCLT Mumbai has admitted the demerger scheme petition between EFC Limited and EFC (I) Limited and fixed 27 November 2026 for final hearing. The scheme remains subject to regulatory and other approvals.
EFC (I) Other Announcement
EFC (I) Ltd has filed its quarterly shareholding pattern for the quarter ended September 30, 2026, as per SEBI Regulation 31(1)(b) requirements.
EFC (I) Acquisition Worth ₹54 Cr
EFC (I) Limited has completed the 100% acquisition of Ultrafresh Modular Solutions Limited via a share swap. The transaction is valued at approximately ₹54 Crore.
- Value
- ₹54.00 Cr
EFC (I) Capital Structure Change
EFC (I) Limited allotted 19,99,996 equity shares on a preferential basis for Rs. 53.999892 Crore, in exchange for a 100% stake in Ultrafresh Modular Solutions.
- Value
- ₹54.00 Cr
EFC (I) Annual General Meeting
EFC (I) Limited held its 42nd Annual General Meeting on September 30, 2026. The meeting covered routine items including adoption of financial statements and director re-appointment.
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.